INTELLIA THERAPEUTICS INC (NTLA)

First Week of February 2025 Options Trading For Intellia Therapeutics (NTLA)

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of...

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin...

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

There's nothing bearish at all about what it reported recently.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Inducement Grant...

This Beaten-Down Stock Could Soar by 354%, According to Wall Street

Maybe the Street is a bit too optimistic on this one.

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment...

Oversold Conditions For Intellia Therapeutics (NTLA)

12 High-Growth Stocks That Could Deliver Parabolic Returns

These 12 innovative companies could deliver exponential returns over the next quarter century.

Why Intellia Therapeutics Stock Plummeted by 20% Today

Seemingly encouraging results from the lab were met with some notable skepticism.

Notable Thursday Option Activity: AVPT, AMAT, NTLA

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81%...

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE...

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street

These stocks haven't performed well this year.

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002...

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...

Interesting NTLA Put And Call Options For November 15th

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational...

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

The Ark Invest portfolio is known for taking aggressive bets.

First Week of NTLA January 2027 Options Trading

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary...

Intellia Therapeutics Enters Oversold Territory (NTLA)

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...